ranQ
ranQ
ranQ
DirectoryIndustriesKnowledgeComparisonsSoon
Sign inCheck visibility
ranQHSG Startup LabelRecognised by the
HSG Startup Label

The first Swiss company directory, built to boost AI visibility.

Product
  • Pricing
  • Directory
  • Industries
Company
  • About
  • Contact
  • Legal
© 2026 cohaga AG · All Rights Reserved · St. Gallen, Switzerland · Imprint742,806 companies indexed · Last updated: today
DirectoryIndustryPharmaceutical IndustryStansQanatpharma AG
Qanatpharma AG Logo
Verified· 2 sources

Qanatpharma AG

Summary

About the company

The core activity of Qanatpharma is the development of new therapeutic strategies for the treatment of diseases caused by microvascular dysfunction. The company is particularly focused on researching and developing medications that improve microvascular function and alleviate the effects of diseases such as cognitive decline, hypertension, and heart failure.

AI-generated
Offering

Products & services

LeadhubOutbound Leads by COHAGA

Looking for direct email addresses and phone numbers?

Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.

Discover Leadhub
Industry:Pharmaceutical Industry
✓ Offered4
Research platform (ARTERIOME)
End-to-end discovery and translation platform for resistance artery research, with bioengineering, multimodal phenotyping, omics analyses, AI-supported target identification and translational research design.
Drug development (GENESiS)
Drug-discovery program for first-in-class small-molecule and biologic solutions to restore resistance artery function, with generative-AI-driven lead discovery and a partner consortium.
Clinical proof-of-concept studies
Proof-of-concept studies for clinical testing of microvascular therapies, including randomized, double-blind Phase II studies, MRI and cognitive tests, and recruitment in Toronto.
Therapy development for cerebrovascular diseases
Development of therapies for subarachnoid hemorrhage, delayed cerebral ischemia and cognitive impairment in heart failure, based on restoring cerebral autoregulation.

Knowledge

No knowledge articles yet

Once Qanatpharma AG has claimed this profile, we'll publish editorial articles and case studies here together.

Get started
Comparisons

Qanatpharma AG in comparison

Soon

Industry comparisons are coming soon

We're preparing industry comparisons that rank Qanatpharma AG by reviews, experience and specialisations.

Is this your company?

Claim the company profile of Qanatpharma AG to make its contact details visible. With a plan we additionally create and publish industry comparisons, articles and much more.

Secure profile

Location

Alter Postplatz 2
6370 Stans

At a glance

Legal form
Corporation
UID
CHE-336.262.668
Founded
2023 · 3 years
Last commercial register change
April 24, 2023
Employees
11 to 20

Similar companies

IP
Innoval Pharma AG
Stans
BB
BHP Bio Health Pharma AG
Hergiswil Nw
PA
Pearsceuticals AG
Hergiswil Nw
RA
RUBIMED AG
Hergiswil Nw